Glucotrack plans to file for an investigational device exemption in the second quarter, with hopes of starting a trial in the ...

Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026RUTHERFORD, N.J., March 27, ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

A major new study investigating the safest and most effective way to monitor blood sugar levels during labour in women with gestational diabetes has ...

Advances in microfluidic biosensors and materials science transformed sweat into a reliable, high-quality data stream capable ...

When Zhang Huchuan's friend spotted a small device on her arm during a trip to Shanxi province, he assumed she had diabetes.

Glucotrack Inc. (GCTK) shares soared nearly 15% in Friday’s pre-market trade after the company announced that it is in a ...

The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood ...

A Connecticut college studies with Type 1 diabetes calls for broader social understanding of chronic health conditions.

Join us in Minneapolis to hear more from keynote speaker Lisa Earnhardt, at DeviceTalks Minnesota on May 4, 2026.

Neurophet partners with US-based Alzheimer's network on imaging AI. South Korean company Neurophet has signed a memorandum of ...

Transitioning from multiple daily injections to a tubeless automated insulin delivery (AID) system significantly improves HbA1c in T1D.